[Therapy concepts for thyroid carcinoma].
| Autor: | Eilsberger F; Klinik für Nuklearmedizin, Universitätsklinikum Marburg, Marburg, Germany., Kreissl MC; Abteilung für Nuklearmedizin, Universitätsklinikum Magdeburg, Magdeburg, Germany., Luster M; Nuclearmedicine, University of Marburg, Marburg, Germany., Pfestroff A; Klinik für Nuklearmedizin, Universitätsklinikum Marburg, Marburg, Germany. |
|---|---|
| Jazyk: | němčina |
| Zdroj: | Laryngo- rhino- otologie [Laryngorhinootologie] 2023 Jul; Vol. 102 (7), pp. 488-495. Date of Electronic Publication: 2023 Apr 03. |
| DOI: | 10.1055/a-1861-7379 |
| Abstrakt: | Theranostics via the sodium iodide symporter (NIS) offer a unique option in differentiated thyroid carcinoma. The diagnostic and therapeutic nuclides have similar uptake and kinetics, making the NIS the most important theranostic target in this disease. Radioiodine refractory thyroid carcinomas (RRTC) are characterised by reduced/absent NIS expression, thus eliminating this structure as a theranostic target. Also due to limited therapeutic options, there are approaches to generate new theranostic targets in RRTC, via the expression of somatostatin receptors (SSTR) or the prostate-specific membrane antigen (PSMA), but the current evidence does not yet allow a final evaluation of the prospects of success. Competing Interests: Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht. (Thieme. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|